Drug Profile
Research programme: CNS disorders therapeutics - Anavex Life Sciences
Alternative Names: ANAVEX 19-144Latest Information Update: 28 Nov 2019
Price :
$50
*
At a glance
- Originator Anavex Life Sciences
- Class Furans; Small molecules
- Mechanism of Action Calcium channel modulators; Chloride channel modulators; Muscarinic receptor modulators; Serotonin modulators; Sigma-1 receptor agonists; Sodium channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease; Amyotrophic lateral sclerosis; Major depressive disorder; Parkinson's disease
- Discontinued Epilepsy
Most Recent Events
- 28 Nov 2019 No recent reports of development identified for preclinical development in Alzheimer's-disease in Europe (IV)
- 28 Nov 2019 No recent reports of development identified for preclinical development in Alzheimer's-disease in Europe (PO)
- 28 Nov 2019 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in USA